Skip to main content
SpringerLink
Log in

In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphy

  • IMAGES THAT TEACH
  • Published:
Journal of Nuclear Cardiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

References

  1. Gillmore JD, Maurer MS, Falk RH, Merlini G, Damy T, Dispenzieri A, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016;133:2404‐12.

    Article  CAS  PubMed  Google Scholar 

  2. Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations (SCAN-MP). ClinicalTrials.gov identifier: NCT03812172. Updated February 8, 2023. Accessed March 2, 2023. https://clinicaltrials.gov/ct2/show/NCT03812172.

  3. Evuzamitide as SPECT/CT Imaging Agent for Diagnosis of Transthyretin Amyloidosis. ClinicalTrials.gov identifier: NCT05635045. Updated February 8, 2023. Accessed March 2, 2023. https://clinicaltrials.gov/ct2/show/NCT05635045.

Download references

Disclosures

This study is funded by Attralus (San Francisco, CA). Dia Smiley and Nicholas Chan receive salary support from the Amyloidosis Foundation. Andrew Einstein has received speaker fees from Ionetix; has received consulting fees from W. L. Gore & Associates; has received authorship fees from Wolters Kluwer Healthcare - UpToDate; and has received grants or grants pending to his institution from Attralus, Canon Medical Systems, Eidos Therapeutics, GE Healthcare, Pfizer, Roche Medical Systems, W. L. Gore & Associates, and XyloCor Therapeutics. Jonathan Wall has intellectual property rights related 124I-AT-01 and is a co-founder and shareholder in Attralus Inc. who licensed the rights to 124I-AT-01. Mathew Maurer reports grant support from NIH R01HL139671 and grants and personal fees from Alnylam, Pfizer, Eidos, Prothena, and Ionis and personal fees from Astra Zeneca, Akcea, Intellia, and Novo Nordisk. Miroslav Sekulic, Stephen Helmke, Mrinali Shetty, Kim Goldner, Denisse D. Santana, and Akiva Mintz have no disclosures.

Author information

Authors and Affiliations

  1. Seymour, Paul, and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA

    Dia Smiley DO, Andrew J. Einstein MD, PhD, Nicholas Chan MD, Denisse D. Santana MD, Mrinali Shetty MD & Stephen Helmke MPH

  2. Department of Radiology, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA

    Andrew J. Einstein MD, PhD & Akiva Mintz MD, PhD

  3. Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York Presbyterian Hospital, New York, NY, USA

    Miroslav Sekulic MD

  4. Amyloidosis and Cancer Theranostics Program, University of Tennessee Graduate School of Medicine, Knoxville, USA

    Kim Goldner CNMT, RT & Jonathan Wall PhD

  5. Seymour, Paul, and Gloria Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York Presbyterian Hospital, 622 West 168th Street, PH12 Stem Room 134, New York, NY, 10032, USA

    Mathew S. Maurer MD

Authors
  1. Dia Smiley DO
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew J. Einstein MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas Chan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akiva Mintz MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Denisse D. Santana MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mrinali Shetty MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Miroslav Sekulic MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kim Goldner CNMT, RT
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jonathan Wall PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Stephen Helmke MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Mathew S. Maurer MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mathew S. Maurer MD.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Smiley, D., Einstein, A.J., Chan, N. et al. In the thick of it: hereditary cardiac amyloidosis identified by 124I-AT-01 PET imaging but not cardiac MRI or SPECT 99mTc pyrophosphate scintigraphy. J. Nucl. Cardiol. 30, 1258–1262 (2023). https://doi.org/10.1007/s12350-023-03267-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-023-03267-7

Search

Navigation